CHMP Backs EU Approval for Corcept's Lifyorli in Ovarian Cancer
CORT has more than doubled off its 52-week low of $28.66.
Summary
The CHMP has recommended EU approval of relacorilant (Lifyorli) combined with nab-paclitaxel for platinum-resistant ovarian cancer. This is a major regulatory milestone that de-risks the EU launch timeline and expands the addressable market for the drug. An EC decision is expected in Q4 2026, which is the next key catalyst. The recommendation follows the U.S. approval and positive Phase 3 ROSELLA data, reinforcing the drug's clinical profile. Corcept's Q2 revenue already surged 32% to $256.1M driven by the Lifyorli launch, and EU approval would add another significant revenue stream.
At the time of this announcement, CORT was trading at $114.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.4B. The 52-week trading range was $28.66 to $126.38. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.